Portal de Periódicos da CAPES

Non-Bleeding Visible Vessel Treatment: Perendoscopic Injection Therapy versus Omeprazole Infusion

1995; Taylor & Francis; Volume: 30; Issue: 9 Linguagem: Inglês

10.3109/00365529509101593

1502-7708

C. Grosso, Alfredo Rossi, Pietro Gambitta, Marta Bini, G. Zanasi, Z. Pirone, R Arcidiacono,

Gastrointestinal disorders and treatments

Background: The non-bleeding visible vessel in a peptic ulcer is the highest risk factor for a bleeding recurrence among not actively bleeding lesions. Perendoscopic injection of sclerosing compounds is usually used as prophylaxis against rebleeding.Methods: Forty-two patients with visible vessels in a peptic ulcer at an emergency endoscopic procedure have been studied: 21 patients underwent prophylactic perendoscopic hemostasis, and 21 patients were infused with omeprazole intravenously.Results: Eight patients (19%), four in each group, had early rebleeding (within 48 h after the enrollment). There was no significant difference between the two types of treatment. At the endoscopic control after 48 h there were significantly more lesions with higher risk of rebleeding (Forrest IIa and IIb) in the group treated with perendoscopic hemostasis.Conclusions: Our data suggest that omeprazole infusion is a valid alternative to injection treatment of non-bleeding visible vessels.